share_log

大摩:维持康方生物(09926)“增持”评级 目标价上调至78港元

Credit Suisse: Maintains a "shareholding" rating for Akeso (09926), with the target price raised to HK$78.

Zhitong Finance ·  Sep 16 10:53  · Ratings

Morgan Stanley released research reports stating that it maintains a 'shareholding' rating for Akeso (09926), and raised the target price from HK$64 to HK$78.

According to the app Smart Finance, Morgan Stanley released research reports stating that it maintains a 'shareholding' rating for Akeso (09926), and raised the target price from HK$64 to HK$78. HARMONi-2 data from Ipsen far exceeded expectations, considering the strong data from Ipsen and consistency in safety, the company's revenue model has been adjusted to reflect overseas revenue contributions, with this year's loss forecast reduced by 30%, next year's loss forecast decreased by 17%, and the profit forecast for 2026 increased by 13%.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment